TY - JOUR
T1 - Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
AU - Sumanasuriya, Semini
AU - Omlin, Aurelius
AU - Armstrong, Andrew
AU - Attard, Gerhardt
AU - Chi, Kim N.
AU - Bevan, Charlotte L.
AU - Shibakawa, Aki
AU - IJzerman, Maarten J.
AU - De Laere, Bram
AU - Lolkema, Martijn
AU - Lorente, David
AU - Luo, Jun
AU - Mehra, Niven
AU - Olmos, David
AU - Scher, Howard
AU - Soule, Howard
AU - Stoecklein, Nikolas H.
AU - Terstappen, Leon W.M.M.
AU - Waugh, David
AU - de Bono, Johann S.
N1 - Publisher Copyright:
© 2018 European Association of Urology
PY - 2018/6
Y1 - 2018/6
N2 - Context: In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic monitoring and as prognostic and predictive biomarkers. However, there is a lack of consensus and standardisation regarding analyses, reporting, and integration of results into specific clinical contexts. A consensus meeting on circulating biomarkers was held to address these topics. Objective: To present a report of the consensus statement on circulating biomarkers in advanced PC. Evidence acquisition: Four important areas of controversy in the field of circulating biomarkers in PC management were identified: known clinical utility of circulating biomarkers; unmet clinical needs for circulating biomarkers in PC care; most pressing blood-based molecular assays required; and essential steps for developing circulating biomarker assays. A panel of 18 international PC experts in the field of circulating biomarkers developed the programme and consensus questions. The panel voted publicly but anonymously on 50 predefined questions developed following a modified Delphi process. Evidence synthesis: Voting was based solely on panellist opinions of the predefined topics and therefore not on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article and in the detailed voting results provided in the Supplementary material. Conclusions: The expert voting results presented can guide the future development of circulating biomarkers for PC care. Notably, the consensus meeting highlighted the importance of reproducibility and variability studies, among other significant areas in need of trials specifically designed to address them. Patient summary: A panel of international experts met to discuss and vote on the use of different blood-based prostate cancer tests, and how they can be used to guide treatment and disease monitoring to deliver more precise and better patient care. A consensus meeting was held to address areas of controversy regarding circulating biomarkers in advanced prostate cancer. A panel of international experts provides a statement of current utility of circulating biomarkers, along with much-needed recommendations to guide biomarker development.
AB - Context: In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic monitoring and as prognostic and predictive biomarkers. However, there is a lack of consensus and standardisation regarding analyses, reporting, and integration of results into specific clinical contexts. A consensus meeting on circulating biomarkers was held to address these topics. Objective: To present a report of the consensus statement on circulating biomarkers in advanced PC. Evidence acquisition: Four important areas of controversy in the field of circulating biomarkers in PC management were identified: known clinical utility of circulating biomarkers; unmet clinical needs for circulating biomarkers in PC care; most pressing blood-based molecular assays required; and essential steps for developing circulating biomarker assays. A panel of 18 international PC experts in the field of circulating biomarkers developed the programme and consensus questions. The panel voted publicly but anonymously on 50 predefined questions developed following a modified Delphi process. Evidence synthesis: Voting was based solely on panellist opinions of the predefined topics and therefore not on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article and in the detailed voting results provided in the Supplementary material. Conclusions: The expert voting results presented can guide the future development of circulating biomarkers for PC care. Notably, the consensus meeting highlighted the importance of reproducibility and variability studies, among other significant areas in need of trials specifically designed to address them. Patient summary: A panel of international experts met to discuss and vote on the use of different blood-based prostate cancer tests, and how they can be used to guide treatment and disease monitoring to deliver more precise and better patient care. A consensus meeting was held to address areas of controversy regarding circulating biomarkers in advanced prostate cancer. A panel of international experts provides a statement of current utility of circulating biomarkers, along with much-needed recommendations to guide biomarker development.
KW - Advanced prostate cancer
KW - Androgen receptor splice variants
KW - Cell-free DNA
KW - Circulating biomarkers
KW - Circulating tumour cells
KW - Consensus
UR - http://www.scopus.com/inward/record.url?scp=85065500153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065500153&partnerID=8YFLogxK
U2 - 10.1016/j.euo.2018.02.009
DO - 10.1016/j.euo.2018.02.009
M3 - Review article
C2 - 31100240
AN - SCOPUS:85065500153
SN - 2588-9311
VL - 1
SP - 151
EP - 159
JO - European Urology Oncology
JF - European Urology Oncology
IS - 2
ER -